Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07166094 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
A Phase 3 study of Endometrial Cancer and Recurrent or Progressive Endometrial Cancer, sponsored by Genmab.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 544
- Enrollment target
- 20
- Study locations
NCT07166094: Recruiting Phase 3 study of Endometrial Cancer and Recurrent or Progressive Endometrial Cancer, sponsored by Genmab.
NCT07166094 is a Phase 3 study of Endometrial Cancer and Recurrent or Progressive Endometrial Cancer that is actively recruiting participants, run by Genmab. The registered enrollment target is 544 participants, roughly in line with the 521-participant average among 181 other Endometrial Cancer trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07166094, a Phase 3 study of Endometrial Cancer and Recurrent or Progressive Endometrial Cancer, is actively recruiting participants, sponsored by Genmab.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 544 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal (50:50) chance of getting either Rina-S or a chemotherapy agent as treatment in this study. The study duration will be approximately 3 years. The treatment duration will be different for every participant, but an average of 4 to 6 months is expected. All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s).
Conditions Studied
Interventions
- DRUG Rina-S
- DRUG IC
Study Locations (20)
Minnesota
- USOR - Minnesota Oncology/ Coon Rapids Clinic - Coon Rapids
- USOR - Minnesota Oncology/Edina Clinic - Edina
- USOR - Minnesota Oncology/ Maple Grove Clinic - Maple Grove
- USOR - Minnesota Oncology/ Maplewood Clinic - Maplewood
- USOR - Minnesota Oncology/ Minneapolis Clinic - Minneapolis
- USOR - Minnesota Oncology/ Woodbury Clinic - Woodbury
Oregon
- Willamette Valley Cancer Institute and Research Center - Eugene - Eugene
- NW Cancer Specs. P.C. - Happy Valley
- USOR - NW Cancer Specs P.C. - Portland
- USOR - NW Cancer Specs. P.C. - Tigard
Georgia
- Emory Winship Cancer Inst. - Atlanta
- Emory Winship Cancer Inst. - Atlanta
- Emory Winship Cancer Inst./Emory Decatur Hospital - Decatur
Texas
- TX Onc - Arlington North - Arlington
- USOR - Texas Oncology - Austin
- USOR - Texas Oncology - Austin
Maryland
- Sinai Hospital - Baltimore
- William Kahlert Reg. Can. Ctr - Westminster
Florida
- SMH - Sarasota - Main Campus - Sarasota
Louisiana
- Trials365, LLC - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 2025-11-28 |
| Est. Completion | 2029-02 |
| Phase | Phase 3 |
What NCT07166094 shows while recruiting
NCT07166094 is an interventional study that assigns participants to a tested intervention. The registered 544 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 521-participant average among 181 other Endometrial Cancer trials with a reported enrollment target.
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Rina-S is the first listed.
NCT07166094 names 20 study sites across 7 states, led by Minnesota, Oregon, Georgia.
Frequently Asked Questions
What is clinical trial NCT07166094 about?
NCT07166094 is a clinical study titled "Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer". The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal (...
What is the current status of trial NCT07166094?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 544 participants. The study started on 2025-11-28. Estimated completion is 2029-02.
What conditions does trial NCT07166094 study?
This clinical trial studies the following conditions: Endometrial Cancer, Recurrent or Progressive Endometrial Cancer.
What interventions are being tested in trial NCT07166094?
The interventions under investigation include: Rina-S (DRUG), IC (DRUG).
Who is sponsoring clinical trial NCT07166094?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07166094 being conducted?
This trial has 20 study locations across Florida, Georgia, Louisiana, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07166094's enrollment target sits among peer trials
544 29th of 181 higher than 153 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
- NCT06170437 · 544 participants · NA
Smoke-free Home Study in Subsidized Housing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI